A Phase 1 interventional study of MDV3100 in Prostate Cancer and Hormone Refractory Prostate Cancer, sponsored by Pfizer. Completed at 9 sites in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2019-10-03.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 33rd largest by enrollment, is the only one that started in 2007, is one of 22 in phase 1, and was the 2nd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Prostatic Neoplasms by Pfizer: 3 open now, 8 under way, 5 of them phase 3. Of 33 finished, 28 (85%) have results posted.
Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 18th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2007, is one of 8 in phase 1, and was the 7th registered.
Pfizer’s Prostatic Neoplasms studies by the year they started, since 1998.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Pfizer’s 42 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response.
This is a Phase 1, open-label, uncontrolled, dose-escalation study with dose-expansion at doses determined to be tolerated. Patients who tolerate the drug and do not progress will be allowed to continue treatment. The study endpoints are safety and tolerability and pharmacokinetics. PSA values will also be collected to look for PSA response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MDV3100
Drug: MDV3100
MDV3100 daily until progression or dose-limiting toxicity
Also known as: enzalutamide, Xtandi
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)
An adverse events (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and non-SAEs.
Time frame: Baseline up to 30 days after last dose of study treatment (approximately maximum of 129 months)
Percentage of Participants With at Least 1 Dose-limiting Toxicity (DLT): Multiple Dose Period
DLT was defined as a national cancer institute's common toxicity criteria for adverse events (NCI-CTCAE) version 3.0 grade 3 or greater toxicity regardless of perceived causality that is not improved by the use of adequate/maximal medical intervention. Grade 3 alopecia, fever without neutropenia, nausea, vomiting, fatigue, and self-limited or medically controllable adverse events were not considered as DLTs.
Time frame: Baseline up to first 35 days of the study treatment in multiple dose period
Maximum Tolerated Dose (MTD) of MDV3100: Multiple Dose Period
Tolerability was defined as if less than (\<) 4/12 in participants with no prior exposure to MDV3100 (chemo-naive) and \< 4/12 prior chemotherapy participants experienced a DLT within the first 35 days of the multiple dose period. For doses higher than 360 mg/day, tolerability was defined if \<8/24 participants previously treated with chemotherapy experience a DLT within the first 35 days of the multiple dose period. MTD was defined as a dose below the intolerable dose.
Time frame: Baseline up to first 35 days of the study treatment in multiple dose period
Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Single Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24 hours post dose on Day 1 of Single Dose Period
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of MDV3100: Single Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours postdose on Day 1 of Single Dose Period
Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of MDV3100: Single Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Single Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Maximum Plasma Concentration (Cmax) of MDV3100: Single Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Apparent Terminal Elimination Half-Life (T1/2) of MDV3100: Single Dose Period
T 1/2 is the time measured for the plasma concentration of MDV3100 to decrease by one half.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Apparent Volume of Distribution (V/F) of MDV3100: Single Dose Period
Volume of distribution is defined as the theoretical volume in which the total amount of MDV3100 would need to be uniformly distributed to produce the desired plasma concentration of MDV3100. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Apparent Total Plasma Clearance (CL/F) of MDV3100: Single Dose Period
Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 24, 48, 72, 96, 120 hours post dose on Day 1 of Single Dose Period
Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Multiple Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Multiple Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Maximum Plasma Concentration (Cmax) of MDV3100: Multiple Dose Period
Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Minimum Observed Plasma Concentration (Cmin) of MDV3100: Multiple Dose Period
Time frame: Pre-dose on Day 1 of Multiple Dose Period
Apparent Total Plasma Clearance (CL/F) of MDV3100: Multiple Dose Period
Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Time frame: Pre-dose, 0.5, 1, 2, 24 hours post dose on Day 84 of Multiple Dose Period
Percentage of Participants With Prostate Specific Antigen (PSA) Response at Day 84: Multiple Dose Period
Prostate-specific antigen is a glycoprotein considered as a biomarker for the response to therapy in men with prostate cancer. A 50 percent (%) decline in PSA from baseline to the PSA level at Day 84 was considered as a PSA response.
Time frame: Baseline, Day 84
| Milestone | MDV3100 (Enzalutamide): No Previous Chemotherapy | MDV3100 (Enzalutamide): Post Chemotherapy |
|---|---|---|
| Started | 15 | 12 |
| 30 mg/day | 3 | 0 |
| 60 mg/day | 3 | 0 |
| 150/160 mg/day | 2 | 1 |
| 240 mg/day | 3 | 0 |
| 360 mg/day | 4 | 2 |
| 480 mg/day | 0 | 6 |
| 600 mg/day | 0 | 3 |
| Completed | 15 | 12 |
| Not completed | 0 | 0 |
| Milestone | MDV3100 (Enzalutamide): No Previous Chemotherapy | MDV3100 (Enzalutamide): Post Chemotherapy |
|---|---|---|
| Started | 65 | 75 |
| 30 mg/day | 3 | 0 |
| 60 mg/day | 15 | 12 |
| 150/160 mg/day | 15 | 13 |
| 240 mg/day | 17 | 12 |
| 360 mg/day | 15 | 13 |
| 480 mg/day | 0 | 22 |
| 600 mg/day | 0 | 3 |
| Completed | 50 | 43 |
| Not completed | 15 | 32 |
| Withdrew: Adverse event | 1 | 8 |
| Withdrew: Psa disease progression | 3 | 6 |
| Withdrew: Radiologic disease progression | 8 | 11 |
| Withdrew: Clinical disease progression | 1 | 3 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Other | 1 | 1 |
An adverse events (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both SAEs and non-SAEs.
| Participants | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day | MDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) | 0 | 6 | 14 | 8 | 6 | 1 | 1 | 10 |
DLT was defined as a national cancer institute's common toxicity criteria for adverse events (NCI-CTCAE) version 3.0 grade 3 or greater toxicity regardless of perceived causality that is not improved by the use of adequate/maximal medical intervention. Grade 3 alopecia, fever without neutropenia, nausea, vomiting, fatigue, and self-limited or medically controllable adverse events were not considered as DLTs.
| percentage of participants | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With at Least 1 Dose-limiting Toxicity (DLT): Multiple Dose Period | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
Tolerability was defined as if less than (\<) 4/12 in participants with no prior exposure to MDV3100 (chemo-naive) and \< 4/12 prior chemotherapy participants experienced a DLT within the first 35 days of the multiple dose period. For doses higher than 360 mg/day, tolerability was defined if \<8/24 participants previously treated with chemotherapy experience a DLT within the first 35 days of the multiple dose period. MTD was defined as a dose below the intolerable dose.
| milligrams per day | MDV3100 (Enzalutamide) : All Participants |
|---|---|
| Maximum Tolerated Dose (MTD) of MDV3100: Multiple Dose Period | 240 |
| microgram*hour per milliliter | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Single Dose Period | 5.43 ± 11.80 | 15.64 ± 3.50 | 38.21 ± 23.64 | 58.39 ± 47.64 | 79.26 ± 19.29 | — | — |
| microgram*hour per milliliter | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of MDV3100: Single Dose Period | 21.2 ± 14.2 | 53.1 ± 4.1 | 145.3 ± 10.0 | 208.5 ± 44.0 | 320.2 ± 12.9 | 363.4 ± 38.7 | 391.9 ± 14.0 |
| microgram*hour per milliliter | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of MDV3100: Single Dose Period | 51.3 ± 39.8 | 92.7 ± 19.0 | 331.5 ± 14.6 | 459.2 ± 32.7 | 706.7 ± 17.7 | 952.7 ± 42.4 | 865.0 ± 34.6 |
| hours | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Single Dose Period | 1.98 (0.42 to 4.00) | 0.50 (0.48 to 1.00) | 0.53 (0.50 to 1.98) | 1.00 (0.57 to 1.00) | 1.03 (0.53 to 2.20) | 1.54 (0.53 to 2.08) | 1.03 (1.03 to 2.00) |
| microgram per milliliter | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of MDV3100: Single Dose Period | 0.43 ± 15.97 | 1.65 ± 28.77 | 3.30 ± 22.85 | 5.19 ± 18.64 | 6.68 ± 39.61 | 5.93 ± 66.03 | 5.17 ± 19.51 |
T 1/2 is the time measured for the plasma concentration of MDV3100 to decrease by one half.
| hours | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Apparent Terminal Elimination Half-Life (T1/2) of MDV3100: Single Dose Period | 164.9 ± 69.8 | 100.5 ± 30.9 | 143.7 ± 34.8 | 138.9 ± 22.6 | 149.1 ± 26.1 | 144.0 ± 68.4 | 130.4 ± 37.7 |
Volume of distribution is defined as the theoretical volume in which the total amount of MDV3100 would need to be uniformly distributed to produce the desired plasma concentration of MDV3100. Apparent volume of distribution after oral dose (V/F) is influenced by the fraction absorbed.
| liters | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Apparent Volume of Distribution (V/F) of MDV3100: Single Dose Period | 131.7 ± 15.6 | 90.5 ± 16.0 | 91.89 ± 13.31 | 103.8 ± 48.5 | 108.2 ± 15.8 | 97.4 ± 30.7 | 126.4 ± 8.8 |
Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| liters per hour | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Apparent Total Plasma Clearance (CL/F) of MDV3100: Single Dose Period | 0.585 ± 39.810 | 0.647 ± 18.988 | 0.453 ± 14.583 | 0.523 ± 32.679 | 0.509 ± 17.711 | 0.504 ± 42.437 | 0.694 ± 34.625 |
| microgram*hour per milliliter | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to 24 Hours Post Dose (AUC[0-24]) of MDV3100: Multiple Dose Period | 60.0 ± 21.0 | 109.8 ± 34.4 | 291.7 ± 24.9 | 395.7 ± 27.4 | 488.9 ± 23.9 | 463.1 ± NA | — |
| hours | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Plasma Concentration (Tmax) of MDV3100: Multiple Dose Period | 2.07 (1.00 to 3.92) | 1.07 (0.50 to 23.67) | 1.00 (0.00 to 25.80) | 1.08 (0.00 to 26.17) | 1.57 (0.48 to 24.08) | 0.00 (0.00 to 0.00) | — |
| microgram per milliliter | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of MDV3100: Multiple Dose Period | 2.76 ± 21.10 | 5.49 ± 28.88 | 14.07 ± 25.36 | 18.91 ± 26.57 | 24.57 ± 21.00 | 27.90 ± NA | — |
| microgram per milliliter | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Minimum Observed Plasma Concentration (Cmin) of MDV3100: Multiple Dose Period | 0.10 ± 0.03 | 0.00 ± 0.00 | 0.04 ± 0.19 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 1.89 ± 0.55 |
Clearance of a MDV3100 is a measure of the rate at which a MDV3100 is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
| liters per hour | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Apparent Total Plasma Clearance (CL/F) of MDV3100: Multiple Dose Period | 0.507 ± 0.111 | 0.580 ± 0.245 | 0.530 ± 0.149 | 0.628 ± 0.179 | 0.755 ± 0.176 | 1.037 ± NA | — |
Prostate-specific antigen is a glycoprotein considered as a biomarker for the response to therapy in men with prostate cancer. A 50 percent (%) decline in PSA from baseline to the PSA level at Day 84 was considered as a PSA response.
| percentage of participants | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day |
|---|---|---|---|---|---|---|---|
| Percentage of Participants With Prostate Specific Antigen (PSA) Response at Day 84: Multiple Dose Period | 33.3 (0.8 to 90.6) | 50.0 (29.1 to 70.9) | 66.7 (44.7 to 84.4) | 75.0 (50.9 to 91.3) | 71.4 (47.8 to 88.7) | 45.5 (16.7 to 76.6) | — |
Collected over Baseline up to 30 days after last dose of study treatment (approximately maximum of 129 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MDV3100 (Enzalutamide) 30 mg/Day | — | 0/3 (0%) | 3/3 (100%) |
| MDV3100 (Enzalutamide) 60 mg /Day | — | 6/27 (22.2%) | 27/27 (100%) |
| MDV3100 (Enzalutamide) 150/160 mg/Day | — | 14/28 (50%) | 27/28 (96.4%) |
| MDV3100 (Enzalutamide) 240 mg /Day | — | 8/29 (27.6%) | 29/29 (100%) |
| MDV3100 (Enzalutamide) 360 mg /Day | — | 6/28 (21.4%) | 28/28 (100%) |
| MDV3100 (Enzalutamide) 480 mg /Day | — | 1/22 (4.5%) | 21/22 (95.5%) |
| MDV3100 (Enzalutamide) 600 mg /Day | — | 1/3 (33.3%) | 3/3 (100%) |
| MDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period | — | 10/18 (55.6%) | 17/18 (94.4%) |
| Event | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day | MDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period |
|---|---|---|---|---|---|---|---|---|
| ConvulsionNervous system disorders | 0/3 | 0/27 | 0/28 | 0/29 | 1/28 | 1/22 | 1/3 | 0/18 |
| Confusional statePsychiatric disorders | 0/3 | 0/27 | 0/28 | 0/29 | 0/28 | 0/22 | 1/3 | 0/18 |
| Myocardial infarctionCardiac disorders | 0/3 | 0/27 | 0/28 | 0/29 | 1/28 | 0/22 | 0/3 | 2/18 |
| PneumoniaInfections and infestations | 0/3 | 0/27 | 1/28 | 0/29 | 0/28 | 0/22 | 0/3 | 2/18 |
| Spinal cord compressionNervous system disorders | 0/3 | 0/27 | 0/28 | 1/29 | 1/28 | 0/22 | 0/3 | 2/18 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/3 | 1/27 | 0/28 | 0/29 | 0/28 | 0/22 | 0/3 | 2/18 |
| Acute myocardial infarctionCardiac disorders | 0/3 | 0/27 | 0/28 | 0/29 | 0/28 | 0/22 | 0/3 | 2/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 2/27 | 0/28 | 0/29 | 0/28 | 0/22 | 0/3 | 0/18 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/27 | 0/28 | 0/29 | 2/28 | 0/22 | 0/3 | 0/18 |
| FatigueGeneral disorders | 0/3 | 0/27 | 0/28 | 2/29 | 2/28 | 0/22 | 0/3 | 0/18 |
| Event | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day | MDV3100 (Enzalutamide) 160 mg /Day: Long Term Dosing Period |
|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 2/3 | 17/27 | 19/28 | 20/29 | 23/28 | 16/22 | 1/3 | 13/18 |
| NauseaGastrointestinal disorders | 1/3 | 6/27 | 11/28 | 6/29 | 19/28 | 11/22 | 2/3 | 0/18 |
| ConstipationGastrointestinal disorders | 2/3 | 10/27 | 8/28 | 7/29 | 11/28 | 6/22 | 1/3 | 6/18 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 7/27 | 8/28 | 3/29 | 4/28 | 9/22 | 1/3 | 8/18 |
| VomitingGastrointestinal disorders | 0/3 | 5/27 | 3/28 | 1/29 | 6/28 | 4/22 | 2/3 | 1/18 |
| Back painMusculoskeletal and connective tissue disorders | 2/3 | 11/27 | 5/28 | 8/29 | 9/28 | 6/22 | 1/3 | 5/18 |
| DizzinessNervous system disorders | 2/3 | 4/27 | 7/28 | 5/29 | 7/28 | 4/22 | 0/3 | 1/18 |
| Sinus headacheNervous system disorders | 2/3 | 0/27 | 0/28 | 0/29 | 0/28 | 0/22 | 0/3 | 0/18 |
| FlatulenceGastrointestinal disorders | 2/3 | 1/27 | 2/28 | 2/29 | 2/28 | 0/22 | 0/3 | 0/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/3 | 11/27 | 8/28 | 7/29 | 8/28 | 5/22 | 0/3 | 8/18 |
Safety population included all enrolled participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 15 | 10 | 8 | 10 | 7 | 3 | 54 |
| >=65 years | 2 | 12 | 18 | 21 | 18 | 15 | 0 | 86 |
| Sex: Female, Male(Participants) | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 3 | 27 | 28 | 29 | 28 | 22 | 3 | 140 |
| Ethnicity (NIH/OMB)(Participants) | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 0 | 1 | 1 | 0 | 0 | 5 |
| Not Hispanic or Latino | 3 | 24 | 28 | 27 | 27 | 22 | 3 | 134 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | MDV3100 (Enzalutamide) 30 mg/Day | MDV3100 (Enzalutamide) 60 mg /Day | MDV3100 (Enzalutamide) 150/160 mg/Day | MDV3100 (Enzalutamide) 240 mg /Day | MDV3100 (Enzalutamide) 360 mg /Day | MDV3100 (Enzalutamide) 480 mg /Day | MDV3100 (Enzalutamide) 600 mg /Day | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 4 |
| White | 3 | 26 | 28 | 28 | 25 | 22 | 3 | 135 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jul 2007 to primary completion in Dec 2008, 16 months.
Results were first posted in Oct 2019, 10 years 9 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 16 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide